take note ..

This was not in any reports and will not be ........ The independent investigators said the trials stretching back in some cases proved the endpoints of safety, the issue of immune response (irrelevant and controllable), mortality negligible and non -existence at higher dose injections, and lower MACE (major adverse cardiac events).

Of the last two, the first low number was well ahead of expectations. The second was signalled out by the investigators as the biggest surprise of the trial.

Comments by the investigators such as even these trials had been materially worse they would have enabled MSB to get regulatory approval......
Cheers Vin